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Introduction
Tissue hypoxia, owing to an inadequate blood supply, is a
common feature of most solid tumours, and breast carci-
noma is no exception. The accessibility of breast carcinomas
has enabled the use of polarographic O2 needle electrodes
to assess tumour oxygenation. Such studies have demon-
strated an overall lower median pO2 level in malignant
tumours compared with benign tumours and normal breast
tissue. Electrode measurements obtained without the use of
general anaesthesia have revealed median pO2 values of
23–28 mmHg for tumours, compared with 42 mmHg for
benign lesions and 54–65 mmHg for normal tissue [1,2]. Of
all readings taken from breast cancers, 30–40% fall below
10 mmHg, which is very rarely seen in normal tissue [1,2].
The study of Vaupel et al also revealed that nearly 40% of
breast malignancies exhibit tumour regions with oxygen con-
centrations below that required for half-maximal radiosensi-
tivity (pO2 <2.5 mmHg) [1].
Radiotherapy and chemotherapy are both commonly
incorporated into breast cancer treatment regimens.
Retrospective studies in other malignancies have deter-
mined that poor tumour oxygenation is the strongest prog-
nostic indicator of radiotherapy treatment outcome [3–5].
In keeping with these findings, measurements of breast
tumour pO2 distribution, prior to radiotherapy, have indi-
cated that oxygen tension is an important modifier of radia-
tion treatment outcome and is sufficient to predict local
response [6]. In addition, the success of hypothermia as
an adjuvant to radiation therapy for breast cancer treat-
ment may be compromised in tumours with histopathology
suggestive of a high level of chronic hypoxia [7]. The
effects of hypoxia on the success of chemotherapy have
not been clearly established. There is, however, direct evi-
dence that hypoxic cells within tumour xenografts are
refractile to chemotherapeutic agents and the quiescent
nature of hypoxic cells may render them insensitive to
agents that specifically target rapidly dividing cells [8,9].
Poor perfusion may limit drug dissemination to hypoxic
regions. In addition, changes in gene expression to enable
the survival of cells under hypoxic conditions may influ-
ence intracellular and extracellular pH. A commonly
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prescribed chemotherapy treatment for breast cancer is
cyclophosphamide, methotrexate, and 5-fluorouracil.
Studies in murine tumours have shown increased
response to cyclophosphamide when combined with
agents that increase tumour oxygenation [10]. The uptake
of 5-fluorouracil by tumour cells grown in vitro can also be
influenced by pH [11].
Hypoxia as a therapeutic target
Although hypoxia can be detrimental to treatment
outcome, it can also be seen as a physiological abnormal-
ity that is restricted to the tumour and is therefore
exploitable. This has lead to the development of bioreduc-
tive drugs that are preferentially cytotoxic towards hypoxic
cells. The prototype bioreductive agent is the quinone-
alkylating agent, mitomycin C, that has been widely used
in combination chemotherapy regimens for breast cancer.
Aside from quinones, there are two other classes of biore-
ductive drugs: nitro compounds and benzotriazine di-N-
oxides. Of particular clinical interest in the latter group is
tirapazamine, SR4233 (TPZ), which is in phase II/III clini-
cal trials in combination with cisplatin. TPZ has shown
increased treatment efficacy compared with cisplatin
alone in malignant melanoma and non-small-cell lung
cancer, and also may be of benefit when combined with
both radiotherapy and cisplatin in head and neck cancer
[12]. Although not extensively studied for the treatment of
breast cancer, partial responses to combined TPZ/cis-
platin treatment have been seen in phase I breast cancer
patients [13].
The toxicity of quinones results from their one electron
reduction to a semi-quinone free radical that covalently
interacts with and damages DNA. In the presence of
oxygen, this free radical can be oxidised back to the
quinone concomitantly generating superoxide. Alterna-
tively, two electron transfer may directly reduce quinones,
or the semi-quinone can be further reduced, to generate a
hydroquinone that can also be toxic. Nitro prodrugs are
reduced by a series of single electron transfers with one,
two, four and six electron reduction generating active
species. Again the toxic nitroradical (one electron
reduced) can be re-oxidised to the parent compound to
release superoxide. Benzotriazine di-N-oxides are also
reduced to a one electron reduced free radical. This free
radical can be recycled by oxygen to generate superoxide;
however, unlike the covalent interaction with DNA exhib-
ited by the free radical species of quinones and nitro com-
pounds, the N-oxide free radical is thought to act as an
oxidising radical that abstracts hydrogen from the bases
within DNA.
Although the precise activation pathway for these com-
pounds differs, the compounds undergo reduction by
endogenous enzymes to their cytotoxic moiety in aerobic
and hypoxic cells but are only cytotoxic under hypoxia as
a result of their back oxidation in the presence of oxygen
(futile cycling). Many endogenous (one and two electron
reducing) enzymes have been implicated in bioreductive
drug activation: cytochrome P450s; cytochrome P450
reductase, xanthine oxidase and cytochrome b5 reduc-
tase (one electron reducing enzymes); DT-diaphorase
(two electron reducing enzyme); and carbonyl reductase
(one and two electron reducing). These enzymes act to
varying degrees and at different stages in a given
prodrug activation.
Studies have shown that activity levels of carbonyl reduc-
tase and DT-diaphorase can be significantly elevated
within human tumour biopsies, whereas cytochrome P450
reductase and cytochrome b5 reductase levels were
equivalent to those in normal tissue [14,15]. A more com-
prehensive analysis of the reductase status of tumours
would allow for the rationale drug design of prodrugs tai-
lored to the enzyme profile of the tumour. Alternatively,
gene therapy can be exploited to achieve the specific
overexpression of these enzymes within the hypoxic region
of the tumour.
Hypoxia-regulated gene therapy
In the same way that hypoxia provides the physiological
stimulus for bioreductive drug activation, it can also act as
a trigger for specific gene transcription. Cell survival in
response to hypoxic stress is dependent on the upregula-
tion of genes supporting anaerobic metabolism and new
blood vessel recruitment. This hypoxic gene activation is
mediated through the transcription factor hypoxia
inducible factor 1 (HIF-1). Recent studies have implicated
a crucial role for HIF-1 in breast cancer progression. HIF-1
overexpression is commonly seen, with higher expression
levels correlating with more aggressive disease [16].
Common to all HIF-1 responsive genes is a hypoxia
responsive element (HRE). Introducing this HRE
sequence into a gene delivery vehicle affords hypoxic reg-
ulation of the expressed gene. The potential of hypoxia
selective gene therapy for cancer was first exemplified by
the work of Dachs et al [17]. Using HRE-regulated expres-
sion of the suicide gene cytosine deaminase, Dachs et al
demonstrated hypoxia-specific sensitisation of tumour
cells to the prodrug 5-fluorocytosine. Subsequent studies
have similarly demonstrated the efficacy of HRE-regulated
herpes simplex virus thymidine kinase activity in ganciclovir
sensitisation [18]. Although this approach offers a level of
selectivity to standard gene-directed enzyme prodrug
therapy, it can be further enhanced when used in combi-
nation with bioreductive drug treatment. Making hypoxia a
prerequisite for both gene expression and drug activation
may reduce cytotoxicity to healthy tissues (Fig. 1).
Reductase enzyme/prodrug pairings of bacterial nitro-
reductase/CB1954 [19], horseradish peroxidase/indole-
3-acetic acid [20], human cytochrome p450s/AQ4NBreast Cancer Research    Vol 3 No 5 Williams et al
[21], DT-diaphorase/quinone EO9 [22] and human
NADPH:cytochrome c p450 reductase/TPZ [23,24] have
been proposed. Gene delivery of cytochrome p450 reduc-
tase into breast tumour cell lines increases the efficacy of
TPZ treatment in vitro [24]. Glioma tumours constitutively
expressing both cytochrome p450 2B6 and cytochrome
p450 reductase showed enhanced tumour growth delay
when treated with cyclophosphamide (metabolised by
cytochrome p450 2B6) and TPZ; however, systemic toxic-
ity was also seen [25]. This may be potentially overcome
by the use of a HRE to restrict expression to the hypoxic
tumour environment. A particularly attractive refinement to
this strategy for the treatment of breast cancer is the use
of dual specificity promoters combining hypoxic regulation
with tissue-specific regulation. The oestrogen receptor
status of breast tumours identifies a cohort of tumours that
have the potential to mount a transcriptional response to
oestrogen. This is mediated through oestrogen responsive
elements that have been successfully combined with HRE
elements to give oestrogen and hypoxic transcriptional
control of a pro-apoptotic gene [26]. Other breast-specific
promoters, for example erbB-2 [27], could be used in con-
junction with a HRE in this approach.
The limited clinical success of cancer gene therapy to
date has been attributed to a lack of tumour-specific trans-
duction. Clinically used viral vectors such as adenovirus
have also been associated with preferential uptake by the
liver and inherent immunogenicity. This necessitates the
development of better, targeted delivery vehicles that
could ideally be given systemically. This has lead to the
ingenious application of obligate anaerobic bacteria as
vectors, which selectively localise and proliferate within
hypoxic cells when administered systemically. Non-patho-
genic bacteria of the genera bifidobacterium and clostridia
have been used to this effect [19,28]. Clostridia have
been successfully used, allowing systemic delivery of
several suicide genes including nitroreductase. An alterna-
tive approach has been to target existing viral vectors to
hypoxic tumour cells. Viral vectors enter cells by receptor-
mediated endocytosis, which can be specifically directed
to receptors that exhibit elevated levels within hypoxic
regions of a tumour. Combined with the use of polymer
coating, which has the advantage of reducing the innate
immunogenicity, vascular endothelial growth factor
peptide coated adenovirus has been re-directed to the
vascular endothelial growth factor receptor [29].
Macrophages that are known to migrate to hypoxic
regions of tumours have also been exploited as a potential
delivery vehicle of HRE-driven therapeutic genes [30].
Conclusions
Tumour hypoxia provides a unique opportunity for selec-
tive exploitation to achieve success in cancer therapy. It
can be harnessed as a trigger for tumour selective drug
activation and therapeutic gene expression, to be used as
a powerful adjunct to conventional therapy where hypoxia
plays an adverse role in treatment outcome. Although
many of the gene therapy approaches are in their infancy,
the potential advantage that may be gained through the
use of a hypoxia-mediated therapeutic provides a strong
rationale for assessing the oxygen status of breast
tumours prior to treatment. The polarographic needle elec-
trode approach is presently seen as the ‘gold standard’ for
the measurement of tumour oxygenation. More readily
available alternative methods for ascertaining hypoxic frac-
tion are currently being developed. Use of the bioreductive
marker pimonidazole is currently being evaluated in cancer
patients. Pimonidazole is preferentially metabolised by
hypoxic cells, and the pimonidazole adducts formed can
be detected in sections or disaggregated tumour samples
using antibodies. Pimonidazole binding has shown excel-
lent concordance with established methodologies for
analysing hypoxia in murine tumours [31]. The expression
of numerous endogenous hypoxia-regulated proteins,
including carbonic anhydrase IX and glucose transporter-
1, is being evaluated for their potential use as surrogate
markers for hypoxia in the clinical setting [32]. Studies
have already demonstrated that carbonic anhydrase IX
upregulation in breast cancer is associated with poor
Figure 1
Hypoxia-regulated gene therapy. Hypoxia may be exquisitely exploited
to achieve selective gene delivery, gene expression and bioreductive
prodrug activation specifically within hypoxic tumour regions. Viral
delivery vehicles can be specifically targeted to surface receptors
upregulated on hypoxic cells or obligate anaerobes can be harnessed
as vectors for their innate ability to colonise these regions. Making
hypoxia a prerequisite for both gene expression and drug activation
may reduce cytotoxicity to healthy tissues that can be achieved by
combining hypoxia responsive element (HRE)-driven gene expression
of a reductase gene with a bioreductive drug. This will allow the
specific activation of the bioreductive drug to a free radical DNA
damaging species within hypoxic cells that is free to diffuse to other
hypoxic cells to exert a bystander effect. Diffusion to healthy aerobic
tissues, in contrast, will result in re-oxidation of the drug to its non-toxic
prodrug. HIF, hypoxia inducible factor 1; e–, electron.tumour outcome [33]. With the advent of non-invasive
approaches to analyse tumour hypoxia [34], utilising stan-
dard imaging techniques already in the clinic, the specific
tailoring of therapy regimes dependent on tumour oxygen
status will provide unprecedented selectivity and thera-
peutic advantage for cancer treatment.
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